dc.contributor.author | Sezer, A. | |
dc.contributor.author | Ozyilkan, O. | |
dc.date.accessioned | 2020-10-20T09:02:57Z | |
dc.date.available | 2020-10-20T09:02:57Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1556-0864 | en_US |
dc.identifier.uri | https://www.jto.org/article/S1556-0864(19)31849-0/pdf | |
dc.identifier.uri | http://hdl.handle.net/11727/4936 | |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.jtho.2019.08.1166 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | ALK positive | en_US |
dc.subject | ROS1 positive | en_US |
dc.subject | Lorlatinib | en_US |
dc.subject | Advanced stage lung cancer | en_US |
dc.title | Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey | en_US |
dc.type | conferenceObject | en_US |
dc.relation.journal | JOURNAL OF THORACIC ONCOLOGY | en_US |
dc.identifier.volume | 14 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.startpage | S558 | en_US |
dc.identifier.endpage | S559 | en_US |
dc.identifier.wos | 000492162203082 | en_US |